Search

Your search keyword '"Garces, Yolanda"' showing total 325 results
Start Over Author "Garces, Yolanda" Publication Year Range Last 10 years
325 results on '"Garces, Yolanda"'

1. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B, Hu, Chen, Komaki, Ritsuko, Masters, Gregory A, Blumenschein, George R, Chang, Joe Y, Lu, Bo, Dicker, Adam P, Bogart, Jeffrey A, Garces, Yolanda I, Narayan, Samir, Robinson, Clifford G, Kavadi, Vivek S, Greenberger, Joel S, Koprowski, Christopher D, Welsh, James, Gore, Elizabeth M, MacRae, Robert M, Paulus, Rebecca, and Bradley, Jeffrey D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Lung, Clinical Trials and Supportive Activities, Genetics, Clinical Research, Cancer
Abstract

PurposeRTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non-small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy, plus or minus cetuximab. Although the study was negative, based on prior evidence that patients with the KRAS-variant, an inherited germline mutation, benefit from cetuximab, we evaluated KRAS-variant patients in RTOG 0617.Experimental designFrom RTOG 0617, 328 of 496 (66%) of patients were included in this analysis. For time-to-event outcomes, stratified log-rank tests and multivariable Cox regression models were used. For binary outcomes, Cochran-Mantel-Haenzel tests and multivariable logistic regression models were used. All statistical tests were two sided, and a P value

Published
2023

4. Sublobar Resection, Stereotactic Body Radiation Therapy, and Percutaneous Ablation Provide Comparable Outcomes for Lung Metastasis-Directed Therapy

Author

Gits, Hunter C., Khosravi Flanigan, Mitra A., Kapplinger, Jamie D., Reisenauer, Janani S., Eiken, Patrick W., Breen, William G., Vu, Linh H., Welch, Brian T., Harmsen, William S., Day, Courtney N., Olivier, Kenneth R., Park, Sean S., Garces, Yolanda I., Hallemeier, Christopher L., Merrell, Kenneth W., Ashman, Jonathan B., Schild, Steven E., Grams, Michael P., Lucido, J. John, Shen, K. Robert, Cassivi, Stephen D., Wigle, Dennis, Nichols, Francis C., Blackmon, Shanda, Tapias, Luis F., Callstrom, Matthew R., and Owen, Dawn

Published
2024
Full Text
View/download PDF

6. Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience

Author

Laughlin, Brady S., Ebrahimi, Sasha, Voss, Molly M., Patel, Samir H., Foote, Robert L., McGee, Lisa A., Garcia, Joaquin, Ma, Daniel J., Garces, Yolanda I., Wittich, Michelle A. Neben, Price, Katharine A., Schmitt, Alessandra, Zhai, Qihui, May, Byron C., Nagel, Thomas H., Hinni, Michael L., Chintakuntlawar, Ashish V., DeWees, Todd A., and Rwigema, Jean-Claude M.

Published
2023
Full Text
View/download PDF

7. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.

Author

Bezjak, Andrea, Paulus, Rebecca, Gaspar, Laurie E, Timmerman, Robert D, Straube, William L, Ryan, William F, Garces, Yolanda I, Pu, Anthony T, Singh, Anurag K, Videtic, Gregory M, McGarry, Ronald C, Iyengar, Puneeth, Pantarotto, Jason R, Urbanic, James J, Sun, Alexander Y, Daly, Megan E, Grills, Inga S, Sperduto, Paul, Normolle, Daniel P, Bradley, Jeffrey D, and Choy, Hak

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Lung, Clinical Research, Lung Cancer, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.5 Radiotherapy and other non-invasive therapies, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Dose Fractionation, Radiation, Dose-Response Relationship, Radiation, Female, Humans, Lung Neoplasms, Male, Middle Aged, Radiosurgery, Treatment Outcome, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposePatients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC.Materials and methodsMedically inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it.ResultsOne hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively.ConclusionThe MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors.

Published
2019

8. Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer

Author

Yu, Nathan Y., DeWees, Todd A., Voss, Molly M., Breen, William G., Chiang, Jennifer S., Ding, Julia X., Daniels, Thomas B., Owen, Dawn, Olivier, Kenneth R., Garces, Yolanda I., Park, Sean S., Sarkaria, Jann N., Yang, Ping, Savvides, Panayiotis S., Ernani, Vinicius, Liu, Wei, Schild, Steven E., Merrell, Kenneth W., and Sio, Terence T.

Published
2022
Full Text
View/download PDF

9. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab

Author

Gao, Robert W., Day, Courtney N., Yu, Nathan Y., Bush, Aaron, Amundson, Adam C., Prodduturvar, Pranitha, Majeed, Umair, Butts, Emily, Oliver, Thomas, Schwecke, Anna J., Moffett, Jenesse N., Routman, David M., Breen, William G., Potter, Ashley L., Rivera-Concepcion, Joel, Hoppe, Bradford S., Schild, Steven E., Sio, Terence T., Lou, Yanyan, Ernani, Vinicius, Ko, Stephen, Olivier, Kenneth R., Merrell, Kenneth W., Garces, Yolanda I., Manochakian, Rami, Harmsen, William S., Leventakos, Konstantinos, and Owen, Dawn

Published
2022
Full Text
View/download PDF

14. Consensus Statement on Proton Therapy in Mesothelioma

Author

Zeng, Jing, Badiyan, Shahed N., Garces, Yolanda I., Wong, Tony, Zhang, Xiaodong, Simone, Charles B., 2nd, Chang, Joe Y., Knopf, Antje C., Mori, Shinichiro, Iwata, Hiromitsu, Meijers, Arturs, Li, Heng, Bues, Martin, Liu, Wei, Schild, Steven E., and Rengan, Ramesh

Published
2021
Full Text
View/download PDF

15. The Importance of Verification CT-QA Scans in Patients Treated with IMPT for Head and Neck Cancers

Author

Evans, Jaden D., Harper, Riley H., Petersen, Molly, Harmsen, William S., Anand, Aman, Hunzeker, Ashley, Deiter, Noelle C., Schultz, Heather, Jethwa, Krishan R., Lester, Scott C., Routman, David M., Ma, Daniel J., Garces, Yolanda I., Neben-Wittich, Michelle A., Laack, Nadia N., Beltran, Chris J., Patel, Samir H., McGee, Lisa A., Rwigema, Jean-Claude M., Mundy, Daniel W., and Foote, Robert L.

Published
2020
Full Text
View/download PDF

16. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer

Author

Manzar, Gohar S., Lester, Scott C., Routman, David M., Harmsen, William S., Petersen, Molly M., Sloan, Jeff A., Mundy, Daniel W., Hunzeker, Ashley E., Amundson, Adam C., Anderson, Jeffrey L., Patel, Samir H., Garces, Yolanda I., Halyard, Michele Y., McGee, Lisa A., Neben-Wittich, Michelle A., Ma, Daniel J., Frank, Steven J., Whitaker, Thomas J., and Foote, Robert L.

Published
2020
Full Text
View/download PDF

17. Impact of radiation dose distribution on nutritional supplementation needs in head and neck cancer radiotherapy: a voxel-based machine learning approach

Author

Madhavan, Sudharsan, primary, Gamez, Mauricio, additional, Garces, Yolanda I., additional, Lester, Scott C., additional, Ma, Daniel J., additional, Mundy, Daniel W., additional, Neben Wittich, Michelle A., additional, Qian, Jing, additional, Routman, David M., additional, Foote, Robert L., additional, and Shiraishi, Satomi, additional

Published
2024
Full Text
View/download PDF

19. Mean Oral Cavity Organ-at-Risk Dose Predicts Opioid Use and Hospitalization during Radiotherapy for Patients with Head and Neck Tumors

Author

Foote, Robert L., primary, Harmsen, W. Scott, additional, Amundson, Adam C., additional, Carr, Alan B., additional, Gamez, Mauricio E., additional, Garces, Yolanda I., additional, Lester, Scott C., additional, Ma, Daniel J., additional, McGee, Lisa A., additional, Moore, Eric J., additional, Neben Wittich, Michelle A., additional, Patel, Samir H., additional, Routman, David M., additional, Rwigema, Jean-Claude M., additional, Van Abel, Kathryn M., additional, Yin, Linda X., additional, Muller, Olivia M., additional, and Shiraishi, Satomi, additional

Published
2024
Full Text
View/download PDF

20. N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial

Author

Sio, Terence T., Blanchard, Miran J., Novotny, Paul J., Patel, Samir H., Rwigema, Jean-Claude M., Pederson, Levi D., McGee, Lisa A., Gamez, Mauricio E., Seeger, Grant R., Martenson, James A., Grover, Yvonne, Neben Wittich, Michelle A., Garces, Yolanda I., Foote, Robert L., Miller, Robert C., and Halyard, Michele Y.

Published
2019
Full Text
View/download PDF

23. Mean Oral Cavity Organ at Risk Dose Predicts Opioid Use and Hospitalization During Radiotherapy for Patients with Head and Neck Tumors

Author

Foote, Robert L., primary, Harmsen, William S., additional, Amundson, Adam C., additional, Carr, Alan B., additional, Gamez, Mauricio E., additional, Garces, Yolanda I., additional, Lester, Scott C., additional, Ma, Daniel J., additional, McGee, Lisa A., additional, Moore, Eric J., additional, Neben Wittich, Michelle A., additional, Patel, Samir H., additional, Routman, David M., additional, Rwigema, Jean-Claude M., additional, Van Abel, Kathryn M., additional, Yin, Linda X., additional, Muller, Olivia M., additional, and Shiraishi, Satomi, additional

Published
2023
Full Text
View/download PDF

24. Sublobar Resection, Stereotactic Body Radiation Therapy, and Percutaneous Ablation Provide Comparable Outcomes for Lung Metastasis-Directed Therapy

Author

Gits, Hunter C., primary, Khosravi Flanigan, Mitra A., additional, Kapplinger, Jamie D., additional, Reisenauer, Janani S., additional, Eiken, Patrick W., additional, Breen, William G., additional, Vu, Linh H., additional, Welch, Brian T., additional, Harmsen, William S., additional, Day, Courtney N., additional, Olivier, Kenneth R., additional, Park, Sean S., additional, Garces, Yolanda I., additional, Hallemeier, Christopher L., additional, Merrell, Kenneth W., additional, Ashman, Jonathan B., additional, Schild, Steven E., additional, Grams, Michael P., additional, Lucido, J. John, additional, Shen, K. Robert, additional, Cassivi, Stephen D., additional, Wigle, Dennis, additional, Nichols, Francis C., additional, Blackmon, Shanda, additional, Tapias, Luis F., additional, Callstrom, Matthew R., additional, and Owen, Dawn, additional

Published
2023
Full Text
View/download PDF

25. Supplementary Data Table 11 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Data Table 3 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Data Table 2 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data Table 4 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

29. Data from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Data Table 7 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Data Table 5 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Data Table 9 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

33. TABLE 2 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

34. TABLE 4 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

35. FIGURE 1 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Data Table 6 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

37. TABLE 3 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

38. TABLE 1 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Data Table 8 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B., primary, Hu, Chen, primary, Komaki, Ritsuko, primary, Masters, Gregory A., primary, Blumenschein, George R., primary, Chang, Joe Y., primary, Lu, Bo, primary, Dicker, Adam P., primary, Bogart, Jeffrey A., primary, Garces, Yolanda I., primary, Narayan, Samir, primary, Robinson, Clifford G., primary, Kavadi, Vivek S., primary, Greenberger, Joel S., primary, Koprowski, Christopher D., primary, Welsh, James, primary, Gore, Elizabeth M., primary, MacRae, Robert M., primary, Paulus, Rebecca, primary, and Bradley, Jeffrey D., primary

Published
2023
Full Text
View/download PDF

42. Management of Multifocal Lung Cancer: Results of a Survey

Author

Leventakos, Konstantinos, Peikert, Tobias, Midthun, David E., Molina, Julian R., Blackmon, Shanda, Nichols, Francis C., Garces, Yolanda I., Hallemeier, Christopher L., Murphy, Stephen J., Vasmatzis, George, Kratz, Sarah L., Holland, William P., Thomas, Charles F., Mullon, John J., Shen, K. Robert, Cassivi, Stephen D., Marks, Randolph S., Aubry, Marie Christine, Adjei, Alex A., Yang, Ping, Allen, Mark S., Edell, Eric S., Wigle, Dennis, and Mansfield, Aaron S.

Published
2017
Full Text
View/download PDF

46. Treatment Outcome of Stereotactic Radiosurgery for Adenoid Cystic Carcinoma: A Case Series of 55 Patients.

Author

Hong, Sukwoo, Garces, Yolanda, Price, Katharine, Shinya, Yuki, Parney, Ian, Link, Michael, and Pollock, Bruce

Subjects
*ADENOID cystic carcinoma, *TREATMENT effectiveness, *STEREOTACTIC radiosurgery, *STEREOTAXIC techniques
Abstract

This article, published in the Journal of Neurological Surgery, examines the treatment outcomes of stereotactic radiosurgery (SRS) for adenoid cystic carcinoma (ACC). The study analyzed data from 55 patients with 65 lesions who underwent SRS for ACC between 1990 and 2020. The results showed that SRS with concomitant chemotherapy was associated with better tumor control in select patients. However, ACC originating in the trachea or lung and an increasing interval from the original diagnosis to SRS were identified as negative prognostic factors. [Extracted from the article]

Published
2024
Full Text
View/download PDF

48. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.

Author

Hu, Chen, Hu, Chen, Komaki, Ritsuko, Masters, Gregory, Blumenschein, George, Chang, Joe, Lu, Bo, Dicker, Adam, Bogart, Jeffrey, Garces, Yolanda, Narayan, Samir, Robinson, Clifford, Kavadi, Vivek, Greenberger, Joel, Koprowski, Christopher, Welsh, James, Gore, Elizabeth, MacRae, Robert, Paulus, Rebecca, Bradley, Jeffrey, Weidhaas, Joanne, Hu, Chen, Hu, Chen, Komaki, Ritsuko, Masters, Gregory, Blumenschein, George, Chang, Joe, Lu, Bo, Dicker, Adam, Bogart, Jeffrey, Garces, Yolanda, Narayan, Samir, Robinson, Clifford, Kavadi, Vivek, Greenberger, Joel, Koprowski, Christopher, Welsh, James, Gore, Elizabeth, MacRae, Robert, Paulus, Rebecca, Bradley, Jeffrey, and Weidhaas, Joanne

Abstract

PURPOSE: RTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non-small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy, plus or minus cetuximab. Although the study was negative, based on prior evidence that patients with the KRAS-variant, an inherited germline mutation, benefit from cetuximab, we evaluated KRAS-variant patients in RTOG 0617. EXPERIMENTAL DESIGN: From RTOG 0617, 328 of 496 (66%) of patients were included in this analysis. For time-to-event outcomes, stratified log-rank tests and multivariable Cox regression models were used. For binary outcomes, Cochran-Mantel-Haenzel tests and multivariable logistic regression models were used. All statistical tests were two sided, and a P value <0.05 was considered significant. RESULTS: A total of 17.1% (56/328) of patients had the KRAS-variant, and overall survival rates were similar between KRAS-variant and non-variant patients. However, there was a time-dependent effect of cetuximab seen only in KRAS-variant patients-while the hazard of death was higher in cetuximab-treated patients within year 1 [HR = 3.37, 95% confidence interval (CI): 1.13-10.10, P = 0.030], death was lower from year 1 to 4 (HR = 0.33, 95% CI: 0.11-0.97, P = 0.043). In contrast, in non-variant patients, the addition of cetuximab significantly increased local failure (HR = 1.59, 95% CI: 1.11-2.28, P = 0.012). CONCLUSIONS/DISCUSSION: Although an overall survival advantage was not achieved in KRAS-variant patients, there is potential impact of cetuximab for this genetic subset of patients. In contrast, cetuximab seems to harm non-variant patients. These findings further support the importance of genetic patient selection in trials studying the addition of systemic agents to radiotherapy. SIGNIFICANCE: The KRAS-variant is the first functional, inherited miRNA-disrupting variant identified in cancer. Our findings support that cetuximab has a potentiall

Published
2023

49. Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review

Author

Mayo, Charles S., Pisansky, Thomas M., Petersen, Ivy A., Yan, Elizabeth S., Davis, Brian J., Stafford, Scott L., Garces, Yolanda I., Miller, Robert C., Martenson, James A., Mutter, Robert W., Choo, Richard, Hallemeier, Christopher L., Laack, Nadia N., Park, Sean S., Ma, Daniel J., Olivier, Kenneth R., Keole, Sameer R., Fatyga, Mirek, Foote, Robert L., and Haddock, Michael G.

Published
2016
Full Text
View/download PDF

50. Supplementary Data from Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617

Author

Thor, Maria, primary, Deasy, Joseph O., primary, Hu, Chen, primary, Gore, Elizabeth, primary, Bar-Ad, Voichita, primary, Robinson, Clifford, primary, Wheatley, Matthew, primary, Oh, Jung Hun, primary, Bogart, Jeffrey, primary, Garces, Yolanda I., primary, Kavadi, Vivek S., primary, Narayan, Samir, primary, Iyengar, Puneeth, primary, Witt, Jacob S., primary, Welsh, James W., primary, Koprowski, Cristopher D., primary, Larner, James M., primary, Xiao, Ying, primary, and Bradley, Jeffrey, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results